How Sglt-2 Inhibitors Improve Glycemic Control in Type 2 Diabetes
Chronic metabolic disease known as type 2 diabetes mellitus (T2DM) is characterised by elevated blood sugar levels and insulin resistance. The development of sodium-glucose cotransporter-2 (SGLT-2) inhibitors is one important development in the treatment of T2DM that has occurred throughout the years. Dapagliflozin-containing Forxiga 10 was created to treat diabetes and has completely changed how glycemic management is approached.